Canada · Delayed Price · Currency is CAD Medicure Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 44% year-over-year to CAD 7.9 million, driven by ZYPITAMAG and pharmacy acquisitions, while net loss narrowed. MC-1 phase III trial progresses, with potential for a lucrative FDA priority review voucher if approved.
Fiscal Year 2025
-
Net revenue rose to CAD 28.9 million in 2025, driven by pharmacy acquisitions and Marley Drug growth, but net loss widened to CAD 7.1 million due to a CMS rebate, R&D, and amortization. AGGRASTAT faced generic pressure, while ZYPITAMAG excelled via Marley Drug.
-
Q3 2025 net revenue rose 58% year-over-year to CAD 8.2 million, driven by pharmacy acquisitions and Zypitamag growth, but net loss was CAD 1.4 million due to lower Aggrastat sales and higher costs. MC-1 phase III trial and new chemical entity development remain key priorities.
-
Q2 2025 net revenue rose 29% year-over-year to $6.7 million, driven by ZYPITAMAG, MARVEY Drug, and new pharmacy acquisitions, while net loss narrowed and adjusted EBITDA improved. Focus remains on product growth, pharmacy expansion, and R&D for new therapies.
-
Q1 2025 revenue was CAD 5.5 million, with a net loss of CAD 694,000 due to higher R&D and lower AGGRASTAT and ZYPITAMAG insured channel sales. Growth was driven by Marley Drug and new pharmacy acquisitions, while the company remains debt free with stable cash.
Fiscal Year 2024
-
Revenue was stable at CAD 21.9 million, with growth in ZYPITAMAG and Marley Drug offset by lower AGGRASTAT sales. Net loss widened to $1 million due to higher R&D and legal expenses. Pharmacy acquisitions and MC1 clinical progress position the company for future growth.
-
Q3 2024 net revenue was $5.2M, with net income rising to $680K due to a legal settlement. AGGRASTAT revenue declined from generic competition, while Marley Drug and ZYPITAMAG sales grew. R&D focus remains on MC1 for PNPO deficiency and new drug development.
-
Q2 2024 saw net revenue of CAD 5.2 million and a net loss of CAD 1.2 million, driven by higher R&D and cost pressures, with AGGRASTAT revenue declining due to generic competition. Focus remains on MC-1 development and expanding Marley Drug and ZYPITAMAG sales.